Markets:

Overview

News

Currencies

International

Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

74.87 +1.74 (+2.38%)

Streaming Delayed Price Updated: 12:53 PM EST, Jan 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Bristol Myers' Lead Cancer Drug Opdivo Formulated As Under Skin Injection At Par With Intravenous Infusion In Kidney Cancer Patients ↗

January 29, 2024

Results from Bristol Myers Squibb's Phase 3 CheckMate -67T trial on subcutaneous Opdivo (nivolumab) for advanced clear cell renal cell carcinoma. Noninferiority compared to IV Opdivo.

Via Benzinga

Don't overlook NASDAQ:HALO—a stock with solid growth prospects and a reasonable valuation. ↗

January 29, 2024

In the world of growth stocks, NASDAQ:HALO shines as a value proposition.

Via Chartmill

3 Biotech Stocks to Sell in January Before They Crash and Burn ↗

January 25, 2024

The biotech industry is one of the most profitable though risky at the same time. Here are three biotech stocks to sell.

Via InvestorPlace

NASDAQ:HALO: good value for what you're paying. ↗

January 19, 2024

HALOZYME THERAPEUTICS INC (NASDAQ:HALO), an undervalued stock with good fundamentals.

Via Chartmill

Halozyme's Ambitious Five-Year Plan: Analysts Optimistic On Growth, Eyeing Market Expansion ↗

January 18, 2024

Explore Halozyme Therapeutics' promising financial outlook up to 2028. Discover revenue forecasts, earnings projections, and market insights.

Via Benzinga

Expert Outlook: Halozyme Therapeutics Through The Eyes Of 4 Analysts ↗

January 18, 2024

Via Benzinga

Expert Outlook: Halozyme Therapeutics Through The Eyes Of 4 Analysts ↗

December 26, 2023

Via Benzinga

NASDAQ:HALO: a strong growth stock preparing for the next leg up?. ↗

November 24, 2023

Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Promising High-Growth Stock in the Midst of Consolidation.

Via Chartmill

Earnings Scheduled For November 6, 2023 ↗

November 06, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.

Via Benzinga

Roche's One Of Largest Selling Cancer Drug Approved Under The Skin Injection Version In Europe ↗

January 16, 2024

Roche's Tecentriq SC, the EU's first subcutaneous PD-(L)1 immunotherapy, approved for faster, 7-minute injections

Via Benzinga

4 Magnificent Healthcare Stocks to Buy in 2024 and Beyond ↗

January 16, 2024

Healthcare stocks have underperformed in 2023, but that is expected to change this year.

Via The Motley Fool

Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation. ↗

January 10, 2024

Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Promising High-Growth Stock in the Midst of Consolidation.

Via Chartmill

Investors should take note of NASDAQ:HALO, a growth stock that remains attractively priced. ↗

January 08, 2024

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is showing decent growth, but is still valued reasonably.

Via Chartmill

Despite its impressive fundamentals, NASDAQ:HALO remains undervalued. ↗

December 29, 2023

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

Via Chartmill

Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation. ↗

December 19, 2023

HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—A High-Growth Stock Gearing Up for Its Next Upward Move.

Via Chartmill

Earnings Outlook For Halozyme Therapeutics ↗

November 03, 2023

Via Benzinga

Despite its growth, NASDAQ:HALO remains within the realm of affordability. ↗

November 02, 2023

NASDAQ:HALO, a growth stock which is not overvalued.

Via Chartmill

NASDAQ:HALO is showing decent growth, but is still valued reasonably. ↗

October 12, 2023

Investors seeking growth at a reasonable cost should explore HALOZYME THERAPEUTICS INC (NASDAQ:HALO).

Via Chartmill

While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable. ↗

December 18, 2023

Investors should take note of NASDAQ:HALO, a growth stock that remains attractively priced.

Via Chartmill

For those who appreciate value investing, NASDAQ:HALO is a compelling option with its solid fundamentals. ↗

December 08, 2023

In a market where value is scarce, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) offers a refreshing opportunity with its solid fundamentals.

Via Chartmill

NASDAQ:HALO is showing good growth, while it is not too expensive. ↗

November 27, 2023

Despite its growth, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) remains within the realm of affordability.

Via Chartmill

NASDAQ:HALO, an undervalued stock with good fundamentals. ↗

November 15, 2023

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) appears to be flying under the radar despite its strong fundamentals.

Via Chartmill

7 Underappreciated Biotech Stocks to Pick Up on the Cheap ↗

November 09, 2023

With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor.

Via InvestorPlace

Topics Economy

Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures ↗

November 09, 2023

Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments.

Via InvestorPlace

Analyst Expectations for Halozyme Therapeutics's Future ↗

October 09, 2023

Via Benzinga

3 Promising Biotech Stocks Flying Under the Radar ↗

November 08, 2023

Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks.

Via InvestorPlace

Millionaire Secrets: 3 Stocks to Turn $1,000 Into a Fortune ↗

October 27, 2023

Are you looking to invest in the stock market and become a millionaire? Here are three stocks to buy to turn $1,000 into a fortune.

Via InvestorPlace

For those who appreciate value investing, NASDAQ:HALO is a compelling option with its solid fundamentals. ↗

October 24, 2023

In a market where value is scarce, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) offers a refreshing opportunity with its solid fundamentals.

Via Chartmill

Opdivo's Subcutaneous Formulation Shows Promise in Advanced Kidney Cancer: Bristol Myers Squibb's Latest Findings ↗

October 19, 2023

Bristol Myers Squibb Co (NYSE: BMY) released topline data from the Phase 3 CheckMate -67T noninferiority trial of a subcutaneous Opdivo (nivolumab) compared to intravenous (IV) Opdivo for advanced or...

Via Benzinga

Why NASDAQ:HALO Is a Standout High-Growth Stock in a Consolidation Phase. ↗

October 11, 2023

Exploring the Growth Potential of HALOZYME THERAPEUTICS INC (NASDAQ:HALO) as It Nears a Breakout.

Via Chartmill

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.